Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPECTRA-TB: Stratified Treatment Regimens for Active TB
NCT07595042Phase 2Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2026
- Primary completion
- Jun 2029
- Countries
- 16
01
Overview
A Phase 2 trial of rifapentine, moxifloxacin in Tuberculosis (TB), sponsored by National Institute of Allergy and Infectious Diseases. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
rifapentinemoxifloxacin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07595042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07595042.